Tag: ASX: CAN
Cann Group expects record revenue growth of 111% in FY23
Pharmaceutical company Cann Group Limited announced its FY23 unaudited results, with its operating revenue expected to be approximately $13.5 million, representing growth of 111 per cent or 2.1 times compared to the prior year revenue.
Featured Article
How a small pet food manufacturer supports a 5x increase in production capacity
For Advanced Pet Care of Australia, scaling into one of Australia’s top pet food manufacturers required more than new production capacity – it required better systems.
